About Curida
Curida is a company based in Elverum (Norway) founded in 2015. Curida has raised $3.2 million across 2 funding rounds from investors including Signet Healthcare Partners and Investinor. The company has 65 employees as of December 31, 2018. Curida offers products and services including Small Molecules Formulations, Liquid Pharmaceuticals, Biologics, and Raw Material Services. Curida operates in a competitive market with competitors including Crown Laboratories, Encube Ethicals, Famar, Formulated Solutions and Contract Pharmaceuticals, among others.
- Headquarter Elverum, Norway
- Employees 65 as on 31 Dec, 2018
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
$20.69 M (USD)47as on Dec 31, 2022
-
Net Profit
-$4.78 M (USD)-186as on Dec 31, 2022
-
EBITDA
-$3 M (USD)-511as on Dec 31, 2022
-
Total Equity Funding
$3.2 M (USD)
in 2 rounds
-
Latest Funding Round
Not available
-
Investors
Signet Healthcare Partners
& 1 more
-
Employee Count
65
as on Dec 31, 2018
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Curida
Curida offers a comprehensive portfolio of products and services, including Small Molecules Formulations, Liquid Pharmaceuticals, Biologics, and Raw Material Services.
Develops formulations for safe medicine supply and manufacturing.
Produces liquid drugs using blow-fill-seal technology for sterile products.
Specializes in monoclonal antibodies production and conjugation services.
Provides raw materials and special pharmaceuticals for pharmacies.
People of Curida
Unlock access to complete
Unlock access to complete
Funding Insights of Curida
Curida has successfully raised a total of $3.2M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Curida
Curida has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Signet Healthcare Partners and Investinor.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in North America and Europe
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Curida
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Curida
Investment portfolio details for Curida
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Curida
Detailed financials for Curida
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Curida Comparisons
Peer comparison for Curida
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Curida
Curida operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Crown Laboratories, Encube Ethicals, Famar, Formulated Solutions and Contract Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
OTC, prescription, skin care, and oral care products are manufactured.
|
|
| Locked | Locked | Locked |
Contract development and manufacturing for topical semisolid formulations are provided.
|
|
| Locked | Locked | Locked |
Contract manufacturing and development services provider
|
|
| Locked | Locked | Locked |
Company offering CDMO services for the pharma (Rx and OTC), medical device, personal care and veterinary medicine sectors
|
|
| Locked | Locked | Locked |
CDMO focused on manufacturing of semi-solid pharmaceutical drugs
|
Detailed competitors of Curida
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Curida
Complete news archive for Curida
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Curida
Curida was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Curida is headquartered in Elverum, Norway.
Curida is a funded company, having raised a total of $3.2M across 2 funding rounds to date.
As of Dec 31, 2018, the latest employee count at Curida is 65.
Annual revenue of Curida is $20.69M as on Dec 31, 2022.
Curida is a CDMO offering its services for the development of iquid dosage forms in formats such as blow fill seals, nasal sprays and bottles. More than 90 of Curidas revenues comes from their exports to 30 countries and they claim to have 40 years of experience in this field. Their development services portfolio includes formulation development, analytical method development and validation, stability studies, tech transfer and regulatory support. Curidas development services cater mainly to the development of nasal and inhalation drug products (OINDP) and other ophthalmic or topical products which are usually administered with the help of a delivery device.
Curida's top competitors include Encube Ethicals, Famar and Crown Laboratories.
Curida offers Small Molecules Formulations, Liquid Pharmaceuticals, Biologics, and Raw Material Services.
Curida has 2 investors. Key investors include Signet Healthcare Partners, and Investinor.